MA40042B1 - Protéines prohémostatiques pour le traitement de saignement - Google Patents
Protéines prohémostatiques pour le traitement de saignementInfo
- Publication number
- MA40042B1 MA40042B1 MA40042A MA40042A MA40042B1 MA 40042 B1 MA40042 B1 MA 40042B1 MA 40042 A MA40042 A MA 40042A MA 40042 A MA40042 A MA 40042A MA 40042 B1 MA40042 B1 MA 40042B1
- Authority
- MA
- Morocco
- Prior art keywords
- bleeding
- treatment
- proteins
- prohemostatic
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
La présente invention concerne des polypeptides fxa recombinés qui peuvent être utilisés comme antidotes pour neutraliser complètement ou en partie un effet anticoagulant d'un inhibiteur de coagulation chez un sujet, de préférence un inhibiteur direct du facteur xa. L'invention concerne des protéines recombinées du facteur xa et une méthode permettant de neutraliser complètement ou en partie un effet anticoagulant d'un inhibiteur de coagulation chez un sujet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14169895 | 2014-05-26 | ||
PCT/NL2015/050377 WO2015183085A1 (fr) | 2014-05-26 | 2015-05-26 | Protéines prohémostatiques pour le traitement d'une hémorragie |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40042B1 true MA40042B1 (fr) | 2020-08-31 |
Family
ID=50774744
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051688A MA51688A (fr) | 2014-05-26 | 2015-05-26 | Protéines prohémostatiques pour le traitement de saignement |
MA40042A MA40042B1 (fr) | 2014-05-26 | 2015-05-26 | Protéines prohémostatiques pour le traitement de saignement |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051688A MA51688A (fr) | 2014-05-26 | 2015-05-26 | Protéines prohémostatiques pour le traitement de saignement |
Country Status (25)
Country | Link |
---|---|
US (4) | US10537618B2 (fr) |
EP (2) | EP3744840A1 (fr) |
JP (3) | JP6640198B2 (fr) |
KR (2) | KR102351728B1 (fr) |
CN (1) | CN106536566A (fr) |
AU (2) | AU2015268149B2 (fr) |
BR (1) | BR112016027649A2 (fr) |
CA (1) | CA2949349A1 (fr) |
DK (1) | DK3149163T3 (fr) |
EA (2) | EA037991B1 (fr) |
ES (1) | ES2813440T3 (fr) |
HR (1) | HRP20201311T1 (fr) |
HU (1) | HUE052098T2 (fr) |
IL (2) | IL249132B (fr) |
LT (1) | LT3149163T (fr) |
MA (2) | MA51688A (fr) |
MX (2) | MX2016015567A (fr) |
NZ (1) | NZ727444A (fr) |
PL (1) | PL3149163T3 (fr) |
PT (1) | PT3149163T (fr) |
RS (1) | RS60706B1 (fr) |
SG (2) | SG10201906329VA (fr) |
SI (1) | SI3149163T1 (fr) |
WO (1) | WO2015183085A1 (fr) |
ZA (1) | ZA201608017B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016027649A2 (pt) | 2014-05-26 | 2017-08-15 | Academisch Ziekenhuis Leiden | Proteínas prohemostáticas para o tratamento de hemorragia |
CN108486197B (zh) * | 2018-03-06 | 2021-10-22 | 爱斯特(成都)生物制药股份有限公司 | 高纯度依度沙班中间体的制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
IE914102A1 (en) | 1990-11-26 | 1992-06-03 | Genetics Inst | Expression of pace in host cells and methods of use thereof |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
DE4203965A1 (de) | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | Antidot fuer hirudin und synthetische thrombininhibitoren |
AT404357B (de) | 1995-06-13 | 1998-11-25 | Immuno Ag | Prothrombin-derivate |
DE19605126A1 (de) | 1996-02-12 | 1997-08-14 | Basf Ag | Thrombinmuteine als Antidot für Thrombininhibitoren |
US6200955B1 (en) | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
EP1728798A1 (fr) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Polypeptides du facteur X de la coagulation avec propiertés d'activation modifiées |
MX2008006313A (es) * | 2005-11-15 | 2008-11-06 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
EP1820508A1 (fr) * | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Polypeptides du facteur de coagulation X avec des propriétés d'activation modifiées |
SG174077A1 (en) * | 2007-04-13 | 2011-09-29 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
EP3824902A1 (fr) * | 2007-09-28 | 2021-05-26 | Portola Pharmaceuticals, Inc. | Antidotes pour inhibiteurs du facteur xa et procédés d'utilisation associes |
TWI465247B (zh) * | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子vii多肽和其用途 |
JP6163304B2 (ja) | 2009-07-15 | 2017-07-12 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 第Xa因子インヒビターの解毒剤の単位用量処方物およびその使用方法 |
MX365612B (es) * | 2012-07-25 | 2019-06-07 | Catalyst Biosciences Inc | Polipeptidos de factor x modificados y usos de los mismos. |
AU2014210830A1 (en) | 2013-01-31 | 2015-07-16 | Pfizer Inc. | Compositions and methods for counteracting Factor Xa inhibition |
US10119101B2 (en) | 2014-04-28 | 2018-11-06 | Ecolab Usa Inc. | Method of minimizing enzyme based aerosol mist using a pressure spray system |
BR112016027649A2 (pt) * | 2014-05-26 | 2017-08-15 | Academisch Ziekenhuis Leiden | Proteínas prohemostáticas para o tratamento de hemorragia |
-
2015
- 2015-05-26 BR BR112016027649A patent/BR112016027649A2/pt active Search and Examination
- 2015-05-26 DK DK15731411.3T patent/DK3149163T3/da active
- 2015-05-26 CA CA2949349A patent/CA2949349A1/fr active Pending
- 2015-05-26 ES ES15731411T patent/ES2813440T3/es active Active
- 2015-05-26 SG SG10201906329VA patent/SG10201906329VA/en unknown
- 2015-05-26 EP EP20177786.9A patent/EP3744840A1/fr active Pending
- 2015-05-26 AU AU2015268149A patent/AU2015268149B2/en active Active
- 2015-05-26 MA MA051688A patent/MA51688A/fr unknown
- 2015-05-26 EA EA201692161A patent/EA037991B1/ru unknown
- 2015-05-26 PT PT157314113T patent/PT3149163T/pt unknown
- 2015-05-26 KR KR1020217011631A patent/KR102351728B1/ko active IP Right Grant
- 2015-05-26 US US15/313,881 patent/US10537618B2/en active Active
- 2015-05-26 KR KR1020167033773A patent/KR102245264B1/ko active IP Right Grant
- 2015-05-26 SI SI201531321T patent/SI3149163T1/sl unknown
- 2015-05-26 MX MX2016015567A patent/MX2016015567A/es unknown
- 2015-05-26 HU HUE15731411A patent/HUE052098T2/hu unknown
- 2015-05-26 WO PCT/NL2015/050377 patent/WO2015183085A1/fr active Application Filing
- 2015-05-26 NZ NZ727444A patent/NZ727444A/en unknown
- 2015-05-26 RS RS20200990A patent/RS60706B1/sr unknown
- 2015-05-26 EP EP15731411.3A patent/EP3149163B1/fr active Active
- 2015-05-26 CN CN201580039023.6A patent/CN106536566A/zh active Pending
- 2015-05-26 MA MA40042A patent/MA40042B1/fr unknown
- 2015-05-26 SG SG11201609811TA patent/SG11201609811TA/en unknown
- 2015-05-26 LT LTEP15731411.3T patent/LT3149163T/lt unknown
- 2015-05-26 PL PL15731411T patent/PL3149163T3/pl unknown
- 2015-05-26 JP JP2017515659A patent/JP6640198B2/ja active Active
- 2015-05-26 EA EA202190813A patent/EA202190813A1/ru unknown
-
2016
- 2016-11-18 ZA ZA2016/08017A patent/ZA201608017B/en unknown
- 2016-11-22 IL IL249132A patent/IL249132B/en active IP Right Grant
- 2016-11-25 MX MX2020013410A patent/MX2020013410A/es unknown
-
2019
- 2019-12-18 US US16/719,875 patent/US11304995B2/en active Active
- 2019-12-18 US US16/719,866 patent/US11357836B2/en active Active
- 2019-12-25 JP JP2019235197A patent/JP2020062039A/ja active Pending
-
2020
- 2020-08-21 HR HRP20201311TT patent/HRP20201311T1/hr unknown
- 2020-09-15 IL IL277377A patent/IL277377B/en unknown
-
2021
- 2021-06-10 AU AU2021203838A patent/AU2021203838B2/en active Active
-
2022
- 2022-05-31 US US17/829,180 patent/US20220288172A1/en active Pending
- 2022-06-24 JP JP2022102258A patent/JP2022134139A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991862A1 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
EA201791866A1 (ru) | Бициклические гетероциклы в качестве ингибиторов fgfr | |
EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890048A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890047A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201891202A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201891201A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890050A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890051A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890049A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
EA201891539A1 (ru) | Соединения, ингибирующие металлоферменты | |
EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
WO2017015622A3 (fr) | Protéines de liaison à gdf11 et leurs utilisations | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
EA201691470A1 (ru) | Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
MX2020005567A (es) | Metodos de tratamiento con asparaginasa. | |
MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
EA201591278A1 (ru) | Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы | |
PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
EA202091865A1 (ru) | Композиции и способы для снижения экспрессии tau | |
EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода |